Label Changes for:
Cayston (aztreonam for inhalation solution)
September 2012
Changes have been made to the ADVERSE REACTIONS sections of the safety label.
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – September 2012
6 ADVERSE REACTIONS
6.2 Postmarketing Experience
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS:
- Dyspnea
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS:
- Arthralgia, Joint swelling

